$RPRX
Royalty Pharma plc

2020 Q2 Form 10-Q Financial Statement

#000180276820000005 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $510.9M $457.6M
YoY Change 11.65%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $42.80M $30.30M
YoY Change 41.25%
% of Gross Profit
Research & Development $5.776M $21.50M
YoY Change -73.13%
% of Gross Profit
Depreciation & Amortization $5.700M $5.700M
YoY Change 0.0%
% of Gross Profit
Operating Expenses $5.776M $21.50M
YoY Change -73.13%
Operating Profit $409.3M $327.9M
YoY Change 24.85%
Interest Expense $34.19M $69.17M
YoY Change -50.57%
% of Operating Profit 8.35% 21.1%
Other Income/Expense, Net $192.6M -$149.1M
YoY Change -229.2%
Pretax Income $602.0M $178.8M
YoY Change 236.73%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0% 0.0%
Net Earnings $442.1M $151.7M
YoY Change 191.39%
Net Earnings / Revenue 86.52% 33.15%
Basic Earnings Per Share $0.09
Diluted Earnings Per Share $0.09 $254.8K
COMMON SHARES
Basic Shares Outstanding 354.0M shares
Diluted Shares Outstanding 354.0M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.472B
YoY Change
Cash & Equivalents $2.443B $593.3M
Short-Term Investments $28.50M
Other Short-Term Assets $12.79M
YoY Change
Inventory
Prepaid Expenses
Receivables $32.00M
Other Receivables $3.000M
Total Short-Term Assets $3.391B
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $430.3M
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $12.29B
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.391B
Total Long-Term Assets $12.29B
Total Assets $15.69B
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.00M
YoY Change
Accrued Expenses $112.0M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $182.2M
YoY Change
Total Short-Term Liabilities $451.0M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $5.730B
YoY Change
Other Long-Term Liabilities $110.0M
YoY Change
Total Long-Term Liabilities $5.840B
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $451.0M
Total Long-Term Liabilities $5.840B
Total Liabilities $6.291B
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $1.571B
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.119M
YoY Change
Treasury Stock Shares
Shareholders Equity $4.157B
YoY Change
Total Liabilities & Shareholders Equity $15.69B
YoY Change

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $442.1M $151.7M
YoY Change 191.39%
Depreciation, Depletion And Amortization $5.700M $5.700M
YoY Change 0.0%
Cash From Operating Activities $489.0M $336.9M
YoY Change 45.15%
INVESTING ACTIVITIES
Capital Expenditures -$475.3M -$23.40M
YoY Change 1931.2%
Acquisitions
YoY Change
Other Investing Activities $226.0M -$134.9M
YoY Change -267.53%
Cash From Investing Activities -$249.4M -$158.3M
YoY Change 57.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.580B -310.1M
YoY Change -609.35%
NET CHANGE
Cash From Operating Activities 489.0M 336.9M
Cash From Investing Activities -249.4M -158.3M
Cash From Financing Activities 1.580B -310.1M
Net Change In Cash 1.819B -131.5M
YoY Change -1483.35%
FREE CASH FLOW
Cash From Operating Activities $489.0M $336.9M
Capital Expenditures -$475.3M -$23.40M
Free Cash Flow $964.3M $360.3M
YoY Change 167.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001802768
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q2 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2019Q4 rprx Deferred Shares Par Or Stated Value Per Share
DeferredSharesParOrStatedValuePerShare
0.000001
CY2020Q2 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
294176000 shares
CY2019Q4 rprx Deferred Shares Shares Issued
DeferredSharesSharesIssued
0 shares
CY2020Q2 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
294176000 shares
CY2019Q4 rprx Deferred Shares Shares Outstanding
DeferredSharesSharesOutstanding
0 shares
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39329
dei Entity Registrant Name
EntityRegistrantName
Royalty Pharma plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
110 E 59th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
883-0200
dei Security12b Title
Security12bTitle
Class A ordinary shares
dei Trading Symbol
TradingSymbol
RPRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
365899235 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2443430000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
283682000 USD
CY2020Q2 us-gaap Trading Securities Debt
TradingSecuritiesDebt
343679000 USD
CY2019Q4 us-gaap Trading Securities Debt
TradingSecuritiesDebt
56972000 USD
CY2020Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
526937000 USD
CY2019Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
452560000 USD
CY2020Q2 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
32307000 USD
CY2019Q4 rprx Accrued Royalty Receivable
AccruedRoyaltyReceivable
33525000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28500000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 USD
CY2020Q2 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
3147000 USD
CY2019Q4 rprx Other Royalty Income Receivable Current
OtherRoyaltyIncomeReceivableCurrent
5241000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
12789000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
92000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
3390789000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
832072000 USD
CY2020Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
11169857000 USD
CY2019Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
10842052000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40258000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
51724000 USD
CY2020Q2 rprx Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
477185000 USD
CY2019Q4 rprx Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
380756000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
162454000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
131280000 USD
CY2020Q2 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
14717000 USD
CY2019Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
42315000 USD
CY2020Q2 us-gaap Equity Method Investments
EquityMethodInvestments
430296000 USD
CY2019Q4 us-gaap Equity Method Investments
EquityMethodInvestments
124061000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45635000 USD
CY2020Q2 us-gaap Assets
Assets
15685556000 USD
CY2019Q4 us-gaap Assets
Assets
12449895000 USD
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
122771000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
31041000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34366000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11177000 USD
CY2020Q2 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
111610000 USD
CY2019Q4 rprx Accrued Purchase Obligation Current
AccruedPurchaseObligationCurrent
0 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
182226000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
281984000 USD
CY2020Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
9215000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
450973000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
333417000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5729622000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5956138000 USD
CY2020Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
18902000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
110000000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2020Q2 us-gaap Liabilities
Liabilities
6290595000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
6308457000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 rprx Shareholders Contributions
ShareholdersContributions
0 USD
CY2019Q4 rprx Shareholders Contributions
ShareholdersContributions
3282516000 USD
CY2020Q2 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2019Q4 rprx Deferred Shares Value Issued
DeferredSharesValueIssued
0 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2557237000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1571399000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2825212000 USD
CY2020Q2 us-gaap Minority Interest
MinorityInterest
5237829000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
35883000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
30515000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2093000 USD
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
2119000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4266000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6141438000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15685556000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12449895000 USD
CY2020Q2 us-gaap Revenues
Revenues
510932000 USD
CY2019Q2 us-gaap Revenues
Revenues
457608000 USD
us-gaap Revenues
Revenues
1011811000 USD
us-gaap Revenues
Revenues
892491000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5776000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21457000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13415000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44448000 USD
CY2020Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
47278000 USD
CY2019Q2 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
72210000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
135290000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
22177000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5733000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5733000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11466000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12332000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42799000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30349000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
80864000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54775000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
101586000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
129749000 USD
us-gaap Costs And Expenses
CostsAndExpenses
241035000 USD
us-gaap Costs And Expenses
CostsAndExpenses
133732000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
409346000 USD
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
29292000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
327859000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
770776000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
758759000 USD
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-8144000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20218000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-13673000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
34189000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
69168000 USD
us-gaap Interest Expense
InterestExpense
87773000 USD
us-gaap Interest Expense
InterestExpense
136434000 USD
CY2020Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
647000 USD
CY2019Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-39414000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-32798000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-65254000 USD
CY2020Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
193895000 USD
CY2019Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-36800000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
40729000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
16944000 USD
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
2724000 USD
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
4474000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
5582000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
14501000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
261000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5662000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
21000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
192630000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-149089000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59704000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-183895000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
601976000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
178770000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
711072000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
574864000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
601976000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
178770000 USD
us-gaap Profit Loss
ProfitLoss
711072000 USD
us-gaap Profit Loss
ProfitLoss
574864000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
159902000 USD
CY2019Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
27057000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
197758000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
55707000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
442074000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
151713000 USD
us-gaap Net Income Loss
NetIncomeLoss
513314000 USD
us-gaap Net Income Loss
NetIncomeLoss
519157000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
1602000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
3189000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6949000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2939000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59674000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2939000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6949000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4541000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
63740000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6128000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
449023000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
156254000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
577054000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
525285000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1624000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
11296000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
447399000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
156254000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
565758000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
525285000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7162693000 USD
CY2020Q2 rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
6691000 USD
CY2020Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
296483000 USD
CY2020Q2 rprx Stock Issued During Period Value Issued For Registration
StockIssuedDuringPeriodValueIssuedForRegistration
63000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
515789000 USD
CY2020Q2 rprx Stock Issued During Period Value Issued To Partnerships
StockIssuedDuringPeriodValueIssuedToPartnerships
1000 USD
CY2020Q2 rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-1000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1909332000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3740000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
86187000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6949000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4705337000 USD
CY2019Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
233533000 USD
CY2019Q2 us-gaap Profit Loss
ProfitLoss
178770000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2939000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
1602000 USD
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1901000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4653214000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6141438000 USD
rprx Noncontrolling Interest Increase From Contributions
NoncontrollingInterestIncreaseFromContributions
1447965000 USD
rprx Noncontrolling Interest Transfers Of Interests
NoncontrollingInterestTransfersOfInterests
0 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
689684000 USD
rprx Stock Issued During Period Value Issued For Registration
StockIssuedDuringPeriodValueIssuedForRegistration
63000 USD
us-gaap Profit Loss
ProfitLoss
624885000 USD
rprx Stock Issued During Period Value Issued To Partnerships
StockIssuedDuringPeriodValueIssuedToPartnerships
1000 USD
rprx Stockholders Equity Value Effect Of Exchange And Reallocation
StockholdersEquityValueEffectOfExchangeAndReallocation
-1000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1909332000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3740000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
86187000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
59674000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
4066000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9394961000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4552079000 USD
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
475629000 USD
us-gaap Profit Loss
ProfitLoss
574864000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2939000 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
3189000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
4228000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4653214000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
1003504000 USD
rprx Proceeds From Cash Collections From Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables
895150000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
69646000 USD
rprx Proceeds From Cash Collections From Royalties Received On Intangible Assets
ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets
73821000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
8548000 USD
rprx Proceeds From Cash Collections From Other Royalties Received On Financing Receivables
ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables
20456000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3597000 USD
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
14458000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45252000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
360000 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
0 USD
rprx Payments For Collateral Posted On Derivative Instruments
PaymentsForCollateralPostedOnDerivativeInstruments
26670000 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35448000 USD
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
0 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
31840000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
14059000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
13415000 USD
rprx Payments For Ongoing Development Stage Funding
PaymentsForOngoingDevelopmentStageFunding
44448000 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
69985000 USD
rprx Payments For Operating Costs And Professional Services
PaymentsForOperatingCostsAndProfessionalServices
47144000 USD
us-gaap Interest Paid Net
InterestPaidNet
83431000 USD
us-gaap Interest Paid Net
InterestPaidNet
130265000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
960108000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
769777000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
15084000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
125117000 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
50000000 USD
rprx Payments To Acquire Equity Securities Fnni
PaymentsToAcquireEquitySecuritiesFNNI
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
150000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
637235000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
353717000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
29262000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
18684000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
574620000 USD
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
1231736000 USD
rprx Payments For Milestones
PaymentsForMilestones
0 USD
rprx Payments For Milestones
PaymentsForMilestones
250000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-922316000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1475537000 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
285355000 USD
rprx Payments For Distributions To Shareholders And Unitholders
PaymentsForDistributionsToShareholdersAndUnitholders
396049000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
284546000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
77858000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
28055000 USD
rprx Payments To Noncontrolling Interests Other
PaymentsToNoncontrollingInterestsOther
0 USD
rprx Proceeds From Noncontrolling Interests Acquisitions
ProceedsFromNoncontrollingInterestsAcquisitions
17359000 USD
rprx Proceeds From Noncontrolling Interests Acquisitions
ProceedsFromNoncontrollingInterestsAcquisitions
0 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
5114000 USD
rprx Proceeds From Noncontrolling Interests Research And Development
ProceedsFromNoncontrollingInterestsResearchAndDevelopment
0 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
12625000 USD
rprx Proceeds From Noncontrolling Interests Other
ProceedsFromNoncontrollingInterestsOther
0 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
94200000 USD
rprx Repayments Of Long Term Debt Scheduled Payments
RepaymentsOfLongTermDebtScheduledPayments
147000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5170396000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
6040000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
8819000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4228000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1918229000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2121956000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-625135000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2159748000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1330895000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
283682000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1924211000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2443430000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
593316000 USD
us-gaap Use Of Estimates
UseOfEstimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The current outbreak of the novel coronavirus, or COVID-19, could materially and adversely affect our results of operations, financial condition and cash flows. The full extent of the impact due to the COVID-19 pandemic will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact. Given the uncertainty around the extent and timing of the potential future spread or mitigation efforts related to the current outbreak of COVID-19, the financial impact cannot be reasonably estimated at this time. Actual results may differ from those estimates. The results for the interim periods are not necessarily indicative of results for the full year.
CY2020Q2 rprx Number Of Noncontrolling Interests Created
NumberOfNoncontrollingInterestsCreated
2 partnership
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets, receivables, and derivatives. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents, and marketable securities balances at June 30, 2020 and December 31, 2019 were held with State Street Bank and Trust, Deutsche Bank, Merrill Lynch, Pierce, Fenner & Smith, and Bank of America, N.A. Our primary operating accounts significantly exceed the FDIC limits.The majority of our royalty assets and receivables arise from contractual royalty agreements that entitle the Company to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography.
rprx Payments To Terminate Derivative Instruments
PaymentsToTerminateDerivativeInstruments
35400000 USD
rprx Proceeds From Collateral Received On Derivative Instruments
ProceedsFromCollateralReceivedOnDerivativeInstruments
45300000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45600000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125121000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
65833000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
190954000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125121000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6159000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
131280000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28500000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
162500000 USD
CY2019Q2 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
125000000.0 USD
CY2020Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
12890243000 USD
CY2020Q2 rprx Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows
892061000 USD
CY2020Q2 rprx Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows
FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows
11998182000 USD
CY2020Q2 rprx Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal
FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal
301388000 USD
CY2020Q2 us-gaap Notes Receivable Net
NotesReceivableNet
11696794000 USD
CY2019Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
12163030000 USD
CY2019Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
868418000 USD
CY2019Q4 us-gaap Notes Receivable Net
NotesReceivableNet
11294612000 USD
CY2019Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
868418000 USD
us-gaap Financing Receivable Allowance For Credit Losses Recovery
FinancingReceivableAllowanceForCreditLossesRecovery
289587000 USD
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
262980000 USD
us-gaap Financing Receivable Change In Present Value Expense Reversal
FinancingReceivableChangeInPresentValueExpenseReversal
2964000 USD
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
108683000 USD
CY2020Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
1193449000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
565958000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40258000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
606216000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
554492000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
51724000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21500000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44400000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3700000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
601976000 USD
us-gaap Profit Loss
ProfitLoss
711072000 USD
CY2020Q2 rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
408602000 USD
rprx Net Income Loss Attributable To Parent Prior To Offering
NetIncomeLossAttributableToParentPriorToOffering
479842000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
33472000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
33472000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
33472000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
33472000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
353979000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
353980000 shares
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Profit Loss
ProfitLoss
711072000 USD
us-gaap Profit Loss
ProfitLoss
574864000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
135290000 USD
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
22177000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11466000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12332000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4340000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5964000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-32798000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-65254000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
40729000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
16944000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
20218000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-13673000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
31840000 USD
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
14059000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5405000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3740000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3398000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-289000 USD
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
937021000 USD
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
799161000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
1003504000 USD
rprx Increase Decrease In Cash Collections On Financing Receivables
IncreaseDecreaseInCashCollectionsOnFinancingReceivables
895150000 USD
rprx Increase Decrease In Debt Securities Available For Sale
IncreaseDecreaseInDebtSecuritiesAvailableForSale
0 USD
rprx Increase Decrease In Debt Securities Available For Sale
IncreaseDecreaseInDebtSecuritiesAvailableForSale
150000000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
-1218000 USD
rprx Increase Decrease In Accrued Royalty Receivable
IncreaseDecreaseInAccruedRoyaltyReceivable
600000 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-150000000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
-2094000 USD
rprx Increase Decrease In Other Royalty Income Receivable
IncreaseDecreaseInOtherRoyaltyIncomeReceivable
-5670000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
12634000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4171000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-45635000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
26352000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13862000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-769000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-34952000 USD
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
960108000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
769777000 USD
us-gaap Transfer Of Investments
TransferOfInvestments
303679000 USD
us-gaap Transfer Of Investments
TransferOfInvestments
0 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
5700000 USD
rprx Settlements With Equity Method Investments
SettlementsWithEquityMethodInvestments
0 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
220000000 USD
rprx Accrued Purchase Obligation Equity Investment
AccruedPurchaseObligationEquityInvestment
0 USD
rprx Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash
RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
1103774000 USD
rprx Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash
RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash
0 USD
rprx Accrued Purchase Obligation
AccruedPurchaseObligation
1610000 USD
rprx Accrued Purchase Obligation
AccruedPurchaseObligation
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
8897000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
4066000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
48378000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Writedown Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax
24022000 USD
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
122800000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
31000000.0 USD

Files In Submission

Name View Source Status
0001802768-20-000005-index-headers.html Edgar Link pending
0001802768-20-000005-index.html Edgar Link pending
0001802768-20-000005.txt Edgar Link pending
0001802768-20-000005-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
formexhibit311.htm Edgar Link pending
formexhibit312.htm Edgar Link pending
formexhibit32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
rprx-20200630.htm Edgar Link pending
rprx-20200630.xsd Edgar Link pending
rprx-20200630_cal.xml Edgar Link unprocessable
rprx-20200630_def.xml Edgar Link unprocessable
rprx-20200630_htm.xml Edgar Link completed
rprx-20200630_lab.xml Edgar Link unprocessable
rprx-20200630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending